Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: Implications for identification of therapeutically active inhibitors

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 6, 2003, Pages 1098-1104

  Sinha, Uma ^a   Lin, Pei Hua ^b   Edwards, Susan T ^b   Wong, Paul W ^b   Zhu, Bingyan ^b   Scarborough, Robert M ^b   Su, Ting ^b   Jia, Zhaozhong J ^b   Song, Yonghong ^b   Zhang, Penglie ^b   Clizbe, Lane ^b   Park, Gary ^b   Reed, Andrea ^b   Hollenbach, Stanley J ^b   Malinowski, John ^b   Arfsten, Ann E ^b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b NONE

Author keywords

Coagulation inhibitors; Factor Xa; Prothrombinase

Indexed keywords

AMINOISOQUINOLINE DERIVATIVE; ANTICOAGULANT AGENT; BENZAMIDINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; C1924 81; C1942 36; C2072 24; C2092 28; C2104 75; C2112 42; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; MACROMOLECULE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RABBIT; THROMBIN TIME; THROMBOSIS;

ANIMALS; BENZAMIDINES; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; ISOQUINOLINES; MALE; MOLECULAR STRUCTURE; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY; THROMBIN; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 12444287963     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000077248.22632.88     Document Type: Article

References (22)

1. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-1840.
2. Betz A. Recent advances in factor Xa inhibitors. Expert Opin Ther Patents. 2001;11:1013-1023.
3. Zhu BY, Huang W, Su T, Marlowe CM, Sinha U, Hollenbach S, Scarborough RM. Discovery of transition state factor Xa inhibitors as potential anticoagulant agents. Curr Topics Med Chem. 2001;1:101-119.
4. Mann KG, Nesheim ME, Church WR, Haley PE, Krishnaswamy S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1-16.
5. Sinha U, Ku P, Malinowski J, Zhu BY, Scarborough RM, Marlowe CK, Lin PH, Hollenbach SJ. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arterio-venous thrombosis. Eur J Pharmacol. 2000;395:51-59.
6. Sturzebecher J, Kopetzki E, Bode W, Hopfner. Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. FEBS Lett 1997;412:295-300.
7. Ostrem JA, al-Obeidi F, Safar P, Safarova A, Stringer SK, Patek M, Cross MT, Spoonamore J, LoCascio JC, Kasireddy P, Thorpe DS, Sepetov N, Lebl M, Wildgoose P, Strop P. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry. Biochemistry. 1998;37:1053-1059.
8. Betz A, Wong P, Sinha U. Inhibition of factor Xa by a peptidyl α ketothiazole involves two steps: evidence for a stabilizing conformational step. Biochemistry. 1999;38:14582-14591.
9. Wright JD, Boudino FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet. 1996;30:445-462.
10. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost. 1993;70:617-624.
11. Krishnaswamy S, Walker RK. Contribution of the prothrombin fragment 2 domain to the function of factor Va in the prothrombinase complex. Biochemistry 1997, 36; 3319-3330.
12. Hemker HC, Giesen PLA, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet rich plasma. Thromb Haemost. 2000;83:589-591.
13. Blackhart BD, Ruslim-Litrus L, Lu CC, Alves VL, Teng W, Scarborough RM, Reynolds EE, Oksenberg D. Extracellular mutations of protease activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol Pharmacol. 2000;58:1178-1187.
14. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 +2 fragment and thrombin-antithrombin complex. Blood. 1982;59:1086-1097.
15. Hollenbach S, Sinha U, Lin PH, Needham K, Frey L, Hancock TE, Wong A, Wolf DL. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thromb Haemost. 1994;71:357-362.
16. Song Y, Clizbe L, Bhakta C, Teng W, Li W, Wu Y, Jia ZJ, Zhang P, Wang L, Doughan B, Su T, Kanter J, Woolfrey J, Wong P, Huang B, Tran K, Sinha U, Park G, Reed A, Malinowski J, Hollenbach S, Scarborough RM, Zhu BY. Design, synthesis and SAR of substituted acrylamides as factor Xa inhibitors. Bioorg Med Chem Lett. 2002;12:1511-1515.
17. Song Y, Clizbe L, Bhakta C, Teng W, Li W, Wong P, Huang B, Sinha U, Park G, Reed A, Scarborough RM, Zhu BY. Substituted acrylamides as factor Xa inhibitors: improving bioavailability by P1 modification. Bioorg Med Chem Lett. 2002;12:2043-2046.
18. Jia ZJ, Wu Y, Huang W, Goldman E, Zhang P, Kanter JP, Woolfrey J, Wong P, Huang B, Sinha U, Park G, Reed A, Scarborough RM, Zhu BY. Design, synthesis and structure-activity relationship studies of the biaryl 1-(2-naphthyl-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. In: Book of abstracts of the 223rd ACS National Meeting; April 7 to 11, 2002; Orlando, Fla. Abstract MEDI-027.
19. Wong AG, Gunn AC, Ku P, Hollenbach S, Sinha U. Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis. Thromb Haemost. 1997;77:1143-1147.
20. Krishnaswamy S, Betz A. Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry. 1997;36:12080-12086.
21. Betz A, Krishnaswamy S. Regions remote from the site of cleavage determine macromolecular substrate recognition by the prothrombinase complex. J Biol Chem. 1998;273:10709-10718.
22. Monteiro RQ, Zingali RB. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation. Thromb Haemost. 2002;87:288-293.